ArticleMedicine2026
Association between C-reactive protein-triglyceride glucose index and overactive bladder: A population-based study from NHANES 2005-2010 and 2015-2018.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Overactive bladder (OAB) is a common urological condition with significant impacts on quality of life and healthcare burden. Chronic inflammation and insulin resistance have been independently linked to bladder dysfunction. The C-reactive protein-triglyceride glucose index (CTI), a novel composite marker reflecting both inflammatory and metabolic status, may provide additional value in assessing OAB risk, but has not been previously studied in this context. We conducted a cross-sectional analysis using data from National Health and Nutrition Examination Survey 2005-2010 and 2015-2018. OAB was defined based on self-reported symptoms of urgency incontinence and nocturia. CTI was calculated as 0.412 × ln (CRP) + TyG, where TyG = ln [fasting triglyceride (mg/dL) × fasting glucose (mg/dL)/2]. Survey-weighted multivariable logistic regression models were used to assess the association between CTI and OAB. Subgroup, interaction, and generalized additive model analyses were performed to explore potential effect modification and nonlinear trends. Discriminative performance was evaluated using receiver operating characteristic curves. A total of 9390 adults were included. Higher CTI levels were significantly associated with increased odds of OAB. In fully adjusted models, each unit increase in CTI was associated with a 17% higher risk of OAB (OR = 1.17, 95% CI: 1.06-1.28, P = .002). Compared to the lowest CTI quartile, the highest quartile showed a 50% increased risk of OAB (OR = 1.50, 95% CI: 1.17-1.93, P = .002). The association persisted across subgroups, with stronger effects observed in females, younger adults, and participants with lower poverty income ratio. Interaction tests confirmed significant effect modification by age (P for interaction < .001) and socioeconomic status (P = .02). Generalized additive model analysis demonstrated a nonlinear positive trend between CTI and OAB prevalence. In receiver operating characteristic analysis, CTI showed superior discriminative ability (AUC = 0.607) compared to CRP (AUC = 0.588) and TyG (AUC = 0.569). CTI is independently associated with the presence of OAB in a representative US adult population. As a composite marker of metabolic and inflammatory burden, CTI may serve as a useful tool for identifying individuals at elevated risk of OAB, particularly among younger and socioeconomically disadvantaged groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.